Please login to the form below

Not currently logged in
Email:
Password:

EUSA Pharma appoints Rolf Hoffmann to its board

He most recently worked at Amgen for over a decade

Roff HoffmannOncology-focused pharmaceutical group EUSA Pharma has added to its board of directors in the form of Rolf Hoffman.

Hoffman, who is currently chairman of Biotest and sits on the board of directors of Genmab, brings over 30 years’ pharmaceutical experience to his new position having served in a number of senior roles in the industry.

He most recently spent 12 years with Amgen as its senior vice president of commercial operations, US and prior to that, he worked for SVP.

Hoffman said: “I have watched EUSA Pharma’s remarkable progress in the three years since it was founded, and am delighted to now help the company achieve its ambitious plans.”

His new role will see him play a role in guiding EUSA’s commercial strategy for its cancer treatments.

Bryan Morton, executive chairman at EUSA Pharma, said: “Rolf’s strategic insight and guidance, based on significant commercial experience in the oncology field will prove invaluable as EUSA launches Qarziba and Fotivda in Europe.”

8th March 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....